Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Putreliximab plus MRG003 vs chemotherapy in recurrent or metastatic nasopharyngeal carcinoma
CTR20251767Phase 3Active
- Sponsor
- Hangzhou Miracogen
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Hangzhou Miracogen. Started May 2025; status: active.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20251767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251767.